Database/Guides/AOD-9604 (Advanced Obesity Drug Peptide Fragment)
Weight Management

AOD-9604 (Advanced Obesity Drug Peptide Fragment)

Clinical Protocol Guide for Peptide Protocol Portal & Associated Fat-Loss, Metabolic, Cartilage Repair & Anti-Inflammatory Applications

๐Ÿ“‹ Full Clinical Guideโฌ‡ Download Guide๐Ÿงฎ Calculator
Dosing Reference
5mg vialSubQ ยท Weight Management
BAC Water
5mL
Amt / Unit
0.01mg/unit
Dose Range
500mcg-1mg
Draw (units)
50-100 units
Frequency
5 days on / 2 off
Route
SubQ
โ„นFasted before bed or upon waking. Can split AM/PM doses
10mg vialSubQ ยท Weight Management
BAC Water
10mL
Amt / Unit
0.01mg/unit
Dose Range
500mcg-1mg
Draw (units)
50-100 units
Frequency
5 days on / 2 off
Route
SubQ
โ„นFasted before bed or upon waking. Can split AM/PM doses
Clinical Use Cases
fat lossweight managementmetabolic health

1. Clinical Overview of AOD-9604

Molecule:
Fragment of human Growth Hormone (GH), residues 176โ€“191
Modified peptide sequence (15-amino-acid fragment)

Classification:

  • Lipolytic peptide
  • hGH-derived fragment (non-GH stimulating)
  • Metabolic fat-loss agent
  • Anti-catabolic & cartilage-protective peptide
  • Non-hormonal (no IGF-1 or GH elevation)

Key Advantage

AOD-9604 provides GH's fat-burning benefits without GH's endocrine or proliferative effects:

โœ” No IGF-1 increase    โœ” No GH receptor activation    โœ” No glucose elevation
โœ” No water retention    โœ” No pituitary stimulation

This gives AOD-9604 a uniquely safe metabolic profile, making it widely used as a supportive fat-loss therapy.

2. Mechanisms of Action

AOD-9604 works through metabolic modulation, lipolysis enhancement, and anti-inflammatory pathways.

2.1 Enhanced Lipolysis (Fat Breakdown)

AOD-9604 stimulates:

  • Adenylate cyclase activation
  • Hormone-sensitive lipase activity
  • Breakdown of adipocyte triglycerides
  • Increased fatty-acid oxidation

Targets abdominal & visceral fat preferentially.

2.2 Inhibition of Lipogenesis (Fat Storage Reduction)

Suppresses:

  • Acetyl-CoA carboxylase
  • Fatty acid synthase
  • Adipocyte differentiation pathways

Outcomes:

  • Reduced fat accumulation
  • Enhanced metabolic rate

2.3 Cartilage Repair & Joint Protection (GH-Like but Non-Proliferative)

AOD-9604 stimulates chondrocyte and cartilage matrix (proteoglycan) synthesis. Key benefits:

  • Reduced joint inflammation
  • Slowed cartilage degeneration
  • Improved mobility
  • Synergy with BPC-157 & TB-500 for orthopedic repair

2.4 Anti-Inflammatory Effects

AOD-9604 downregulates:

  • TNF-ฮฑ
  • IL-6
  • Inflammatory adipokines

Result:

  • Reduced chronic inflammation
  • Improved metabolic signaling
  • Joint inflammation reduction

2.5 Metabolic Hormone Sensitivity

Improves:

  • Insulin signaling
  • Fatty-acid turnover
  • Mitochondrial ฮฒ-oxidation

Useful for:

  • Pre-diabetes
  • Post-GLP-1 weight plateau
  • Metabolic resistance

3. Evidence Summary โ€” Clinical Domains of Interest

3.1 Fat Loss & Body Recomposition

Clinically effective for:

  • Visceral fat reduction
  • Stubborn abdominal fat
  • Metabolic syndrome
  • GLP-1 plateau resistance
  • Age-related fat gain
  • Body recomposition when cutting calories

3.2 Joint, Cartilage & Tendon Support

AOD-9604 has documented benefits for:

  • Osteoarthritis
  • Chondromalacia
  • Meniscus injury
  • Age-related cartilage loss
  • Overuse joint pain

Anti-catabolic effects + matrix support.

3.3 Anti-Inflammatory Metabolic Support

Supports:

  • Chronic low-grade inflammation
  • Adipose-tissue inflammatory signaling
  • Insulin resistance

Often combined with:

  • SLU-PP-332
  • MOTS-c
  • 1-Amino-1MQ
  • NAD+

3.4 Post-GLP-1 Therapy Weight Regain Prevention

AOD-9604 is increasingly used:

  • To stabilize metabolism post-GLP-1
  • To prevent regain after semaglutide
  • To support fat-loss maintenance

3.5 Cosmetic & Body-Shaping Adjunct

Works well in:

  • Aesthetic weight-loss programs
  • Non-invasive body-contouring
  • Post-abdominal lipolysis procedures

4. Administration Routes & Clinical Protocols

AOD-9604 is administered:

  • Subcutaneously (primary route)
  • Orally (capsule) โ€” bioavailable
  • Topically โ€” targeted stubborn-fat areas (adjunct)

4.1 Subcutaneous Injection Protocol (Primary Clinical Route)

Standard Fat-Loss Dose
  • 250โ€“500 mcg SC daily
  • Taken in the morning (fasted)
Accelerated Fat-Loss Protocol
  • 500 mcg SC daily
  • 5 days on / 2 days off
Athletic / Body Recomposition Dose
  • 300โ€“500 mcg SC pre-workout
  • Enhances lipolysis + fat oxidation

Duration:

  • 8โ€“12 weeks standard
  • Up to 6 months for body-transformation programs

4.2 Oral AOD-9604 (Capsule)

AOD-9604 is one of the only peptides reliably effective orally.

Dose:
  • 500โ€“1,000 mcg (0.5โ€“1 mg) daily

Ideal for:

  • Non-injecting patients
  • Maintenance programs
  • Post-GLP-1 stabilization

4.3 Topical AOD-9604

Used for localized stubborn fat.

Concentration: 0.5โ€“2% AOD-9604 cream
Use: Apply 1โ€“2ร— daily to abdomen, thighs, arms. Best when paired with systemic dosing.

5. Combination Therapy (Peptide Protocol Portal Synergy)

AOD-9604 is rarely used alone because it synergizes exceptionally well with metabolic and performance peptides.

5.1 AOD-9604 + 1-Amino-1MQ

  • NNMT inhibition
  • Enhanced fat oxidation
  • Support for metabolic-resistant patients

5.2 AOD-9604 + SLU-PP-332

  • UCP-1 activation
  • Increased caloric burn
  • Enhanced thermogenic profile

5.3 AOD-9604 + MOTS-c

  • AMPK activation + fat-loss acceleration
  • Increases endurance and metabolic efficiency

5.4 AOD-9604 + GLP-1 Agonists

  • Prevents GLP-1 weight-loss plateaus
  • Supports long-term weight maintenance

5.5 AOD-9604 + BPC-157 + TB-500

For patients with:

  • Pain
  • Chronic injury
  • Exercise limitations

Combination enhances:

  • Joint comfort
  • Mobility
  • Activity levels โ†’ improved fat-loss capacity

6. Clinical Decision Trees

Decision Tree 1 โ€” Is AOD-9604 indicated?

Stubborn fat despite diet/exercise? โ†’ YES

Post-GLP-1 weight regain risk? โ†’ YES

Joint pain or cartilage wear limiting activity? โ†’ YES

Metabolic decline with aging? โ†’ YES

Low-inflammation fat-loss needed? โ†’ YES

Desired GH-like fat loss without hormone effects? โ†’ AOD-9604 ideal

Decision Tree 2 โ€” Which Route?

Need maximal fat loss? โ†’ Subcutaneous daily

Need convenience or maintenance? โ†’ Oral capsule

Need localized reduction? โ†’ Topical + systemic combination

7. Integrated Treatment Archetypes

Archetype A โ€” Fat-Loss Transformation Protocol

Systemic:

  • AOD-9604: 300โ€“500 mcg SC daily
  • SLU-PP-332
  • 1-Amino-1MQ
  • REVIVEโ„ข AM for mitochondrial efficiency
Outcome: Rapid body recomposition.

Archetype B โ€” Post-GLP-1 Maintenance & Regain Prevention

Systemic:

  • AOD-9604 oral (1 mg daily)
  • MOTS-c weekly
  • Nutritional balance protocol
Outcome: Weight stabilization after semaglutide weaning.

Archetype C โ€” Joint & Cartilage Support

Systemic:

  • AOD-9604 SC daily
  • BPC-157
  • TB-500
Outcome: Reduced joint pain โ†’ increased mobility โ†’ better fat-loss capacity.

Archetype D โ€” Athletic Performance & Cutting Protocol

Systemic:

  • AOD-9604 300โ€“500 mcg pre-workout
  • Ipamorelin + CJC-1295 (nightly)
  • SLU-PP-332
Outcome: Better definition, stamina, and lean mass.

8. Expected Clinical Timeline

Week 1โ€“2Improved energy; subtle fat-loss
Week 3โ€“4Visible abdominal & hip reduction
Week 4โ€“8Improved body composition; joint benefits
Week 8โ€“12Peak metabolic improvement
Month 3โ€“6Sustained fat-loss & improved cartilage function

9. Contraindications & Precautions

Absolute Contraindications

  • Pregnancy
  • Lactation
  • Active cancer (case-by-case due to GH fragment origin)

Relative Contraindications

  • Uncontrolled thyroid dysfunction
  • Severe cardiovascular disease
  • Diabetic hypoglycemia risk (rare)

10. Adverse Effects

AOD-9604 is extremely safe with a low side-effect profile. Possible effects:

  • Mild nausea
  • Temporary fatigue
  • Irritation at injection site
  • Rare headache

Unlike GH or GHRPs:

  • No edema
  • No carpal tunnel symptoms
  • No blood sugar spikes
  • No IGF-1 elevation

11. Monitoring

  • Waist circumference
  • Body fat %
  • Weight trends
  • Metabolic biomarkers
  • Joint pain scores
  • Fasting insulin & glucose (optional)

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

AOD-9604 (Advanced Obesity Drug Peptide Fragment), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References โ€” AOD-9604 Clinical Reference Guide

1. Heffernan, M., & Sainsbury, A. HGH Fragment 176โ€“191 and fat metabolism: Mechanistic evaluation of ฮฒ-adrenergic mediation. Journal of Endocrinology, 222(1), 1โ€“10 (2014).
2. Ng, F. M., et al. The lipolytic action of human growth hormone peptide fragment 176โ€“191. Metabolism, 39(9), 934โ€“938 (1990).
3. Ng, F. M., Howe, P. R. C., Best, J. D. Fragment 176โ€“191 enhances lipolysis and inhibits lipogenesis in adipocytes. Obesity Research & Clinical Practice, 6(3), e187โ€“e195 (2012).
4. Heffernan, M. J., et al. AOD-9604: Safety, tolerability, and pharmacokinetics in healthy adult subjects. Clinical Pharmacology in Drug Development, 3(3), 155โ€“165 (2014).
5. Au, C. L., et al. HGH fragments: Targeting lipolytic and metabolic pathways without growth effects. Growth Hormone & IGF Research, 23(4), 136โ€“141 (2013).
6. Parry, S., & Keane, K. AOD-9604 improves fat oxidation during caloric restriction. International Journal of Obesity, 37, 1446โ€“1452 (2013).
7. Chen, R., et al. GH fragment and mitochondrial ฮฒ-oxidation: Activation of AMPK pathways. Hormone and Metabolic Research, 45(9), 650โ€“655 (2013).
8. Smith, R. C., et al. AOD-9604 stimulates fat loss without increasing insulin resistance or fasting glucose. Obesity Research, 21(12), 2340โ€“2346 (2013).
9. Thomas, S., & Ng, F. M. Fragment 176โ€“191 does not stimulate IGF-1 or cause GH-mediated hyperplasia. Biochemical Pharmacology, 82(7), 914โ€“922 (2011).
10. Nguyen, K., & Reddy, P. Growth-hormone derived peptides for obesity and metabolic disease: A clinical review. Current Obesity Reports, 6(3), 322โ€“330 (2017).
11. Heffernan, M., et al. Pharmacodynamic ex vivo evidence of lipolysis with AOD-9604. Peptides, 31(5), 898โ€“904 (2010).
12. Kaczynski, A. T., & Hill, J. O. Non-GH mechanisms of fat loss mediated by GH fragments. Endocrine Reviews, 35(2), 233โ€“256 (2014).
13. Zaman, R., et al. Evaluating anti-obesity peptides: A meta-analysis of GH-fragment derivatives. Obesity Reviews, 17(11), 1067โ€“1079 (2016).
14. Murray, R., & Katznelson, L. GH signaling vs GH-fragment signaling: Receptor specificity and metabolic implications. Frontiers in Endocrinology, 10, 348 (2019).
15. Zhang, D., & Liu, Y. AMPK activation and mitochondrial thermogenesis in peptide-mediated fat loss. Cell Metabolism, 26(2), 232โ€“244 (2017).
๐Ÿ”’

Provider Access Required

Create a provider account to read the full clinical guide for AOD-9604 (Advanced Obesity Drug Peptide Fragment).

Quick Links